The Drug-drug Interaction of SP2086 and Valsartan

Hengrui Medicine

Status and phase

Completed

Phase 1

Conditions

Type 2 Diabetes

Treatments

Drug: SP2086

Drug: Valsartan

Study type

Interventional

Funder types

Industry

Identifiers

NCT02815657

HR-SP-106

Details and patient eligibility

About

The purpose of the study is to investigate the potential interaction between SP2086 and Valsartan after multiple oral doses treatment in healthy adult volunteers.

Full description

This is an open-label (volunteers will know the names of treatments they are assigned) single-center and cross-over study of SP2086 and Valsartan in healthy adult volunteers. All subject were randomized into two groups, and the drugs will be administered according to the AB and BA sequences, all subjects must completed the two stages(A and B). The A sequence was that Valsartan was taken at 160mg qd on Days1-Day12; SP2086 will be administered orally (by mouth) as 200mg on Days 8-Day12.The B sequence was that SP2086 was taken at 200mg qd dose on Days 8-Day12.There were 6 days washout period between the two stages. The whole study needs 31 days.

Enrollment

16 patients

Sex

All

Ages

18 to 45 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Healthy volunteers with a body mass index(BMI) between 19 and 24 Kg/m2
Had signed the informed consent himself or herself.

Exclusion criteria

Have the abnormal lab or other examination results and the change have clinical significance.
History of or current clinically significant medical illness as determined by the Investigator.
Have a family history of thyroid cancer, submandibular gland cancer or long QT syndrome
Known allergy to SP2086 or Glyburide or any of the excipients of the formulation of SP2086 or Glyburide.
History of using the sulfa or sulfonylureas or DPP-IVor GLP-1 drugs or other similar structure drugs.
History of severe unconsciousness hypoglycemia
History of any surgery prior to screening in 6 months.
History of blood donation≥400 mL prior to screening in 3 months or participate in blood donation,or by blood transfusion in one month.
History of participate any drug or medical device prior to screening in 3 months.
Within a month before the screening using any prescription drugs, over-the-counter drugs, Chinese herbal medicine (especially oral antidiabetics drugs) or food supplements( vitamins).
2 days before the randomization ,the patients can not ban alcohol, tobacco, or reference food or drink containing caffeine or xanthine , or vigorous exercise, or there are other factors that can affect drug absorption, distribution, metabolism and excretion.
The hepatitis B surface antigen, hepatitis c antibody, HIV antibody and syphilis antibody was positive.
Pregnancy or lactation women, or a fertility male or female is not willing to contraception during test.
Researchers considered that there was any situation that may cause the participants can't finish this study or bring any obvious risk to subjects.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

None (Open label)

16 participants in 2 patient groups

SP2086 and Valsartan

Active Comparator group

Description:

All subject were randomized into two groups,and the drugs will be administered according to the AB and BA sequences,all subjects must completed the two stages(A and B).The A sequence was that Valsartan was taken at 160mg qd on Days1-Day12; SP2086 will be administered orally (by mouth) as 200mg on Days 8-Day12.The B sequence was that SP2086 was taken at 200mg qd dose on Days 8-Day12.There were 6 days washout period between the two stages.The whole study needs 31 days.This group patient was given treatment from A stage to B stage.

Treatment:

Drug: SP2086

Drug: Valsartan

Valsartan and SP2086

Active Comparator group

Description:

Treatment:

Drug: SP2086

Drug: Valsartan